Janux Therapeutics (NASDAQ:JANX) Upgraded to Strong-Buy at Lifesci Capital

Lifesci Capital upgraded shares of Janux Therapeutics (NASDAQ:JANX) to a strong-buy rating in a report issued on Friday,Zacks.com reports.

A number of other research analysts have also recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. Scotiabank raised their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 4th. Stifel Nicolaus upped their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. UBS Group assumed coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. Finally, BTIG Research boosted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $54.10 on Friday. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -46.24 and a beta of 3.29. Janux Therapeutics has a fifty-two week low of $7.79 and a fifty-two week high of $71.71. The stock has a fifty day moving average price of $54.43 and a 200-day moving average price of $47.50.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics’s quarterly revenue was down 82.6% on a year-over-year basis. Research analysts predict that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00. Following the sale, the chief executive officer now owns 242,054 shares of the company’s stock, valued at approximately $16,217,618. The trade was a 5.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $50.02, for a total value of $92,186.86. Following the transaction, the insider now owns 6,371 shares of the company’s stock, valued at $318,677.42. The trade was a 22.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 91,843 shares of company stock valued at $5,130,437. Corporate insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JANX. Amalgamated Bank raised its position in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares in the last quarter. Plato Investment Management Ltd purchased a new stake in Janux Therapeutics in the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Janux Therapeutics in the 2nd quarter worth approximately $151,000. Finally, AQR Capital Management LLC bought a new position in shares of Janux Therapeutics in the 2nd quarter worth $215,000. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.